Table A3.
Model | P* | HR | 95% CI |
---|---|---|---|
Progression-free survival, n = 48 | |||
VEGF model† | .0309 | 0.904‡ | 0.825 to 0.991 |
Age | .0368 | 0.438 | 0.202 to 0.951 |
Performance status§ | .0155 | 2.477 | 1.188 to 5.166 |
PDGF model | .1306 | 0.992 | 0.981 to 1.002 |
Age | .0918 | 0.516 | 0.239 to 1.113 |
Performance status§ | .0514 | 2.035 | 0.996 to 4.158 |
Overall survival, n = 48 | |||
VEGF model† | .0745 | 0.924‡ | 0.848 to 1.008 |
Age | .1172 | 0.561 | 0.273 to 1.156 |
Performance status§ | .1591 | 1.627 | 0.826 to 3.202 |
PDGF model | .5853 | 0.997 | 0.987 to 1.007 |
Age | .2846 | 0.682 | 0.339 to 1.374 |
Performance status§ | .3506 | 1.372 | 0.706 to 2.668 |
Abbreviations: HR, hazard ratio; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor.
All P values are two-sided.
There were eight VEGF measurements below the detectable range; therefore, we imputed those values by the lowest value of the VEGF samples measured.
VEGF raw values were divided by 100 to give a more interpretable HR.
Performance status indicates Eastern Cooperative Oncology Group performance status of 0 v 1 or 2.